Novel Therapy with Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
x tang,qifeng zhou,zhi jin,zheng fu,chen ye,xizhi shi,aixin sun,denlong wu
DOI: https://doi.org/10.1016/j.bbmt.2011.12.050
2012-01-01
Biology of Blood and Marrow Transplantation
Abstract:In order to improve the graft versus leukemia (GVL) effect of DLI, we investigated the efficacy and safety of combining interferon-α with DLI (aDLI) in patients with high risk acute leukemia (AL) who relapsed after allo-HSCT, and compared the efficacy, toxicity and leukemia free survival (LFS) of aDLI and traditional donor lymphocyte infusion (tDLI) in our transplantation center. Sixteen acute leukemia patients were treated with interferon-α-2b therapy at a dose of 3×106U/day subcutaneously for 5 days followed by G-CSF mobilized donor peripheral stem cell infusion. (termed with “aDLI”). The median duration of IFN-α treatment was 17 (5-50) days, and the median CD3+ cells dose was 9.25×107/kg (4-20×107/kg). In parallel, we retrospectively analyzed the results of tDLI for 14 AL patients with hematologic relapse post allo-HSCT treated in the same period in our center, and compared the efficacy, toxicity and LFS of tDLI with aDLI. Patients treated on the aDLI protocol included 9 ALL and 7 AML, with a median age of 26.5 years. Fourteen of 16 patients had high risk AL. The median relapse time was 5.5 (range, 1-25) months post transplant. Salvage chemotherapy was administrated in 7 patients before aDLI, with only 3 patients achieved CR. The overall CR rate for aDLI protocol was 75% (12/16), with CR rate of aDLI alone at 66.7% (6/9). The median time from aDLI to bone marrow CR was 7 (6-14) days, and the median time to molecular CR (MCR) and full donor chemerism (median level was 96.3%) in responsive patients were 2 weeks post DLI. With a median follow-up of 5.5 (range, 1-34) months, 7 patients were alive with durable molecular CR. Two-year LFS was 50%. Treatment related toxicities included episode of fever, GVHD and myelosuppression. The tDLI group had similar demographic characteristics with disease subtypes, transplant and relapse history. Compared to tDLI, the aDLI protocol had higher CR rate (75.0% vs 14.3%, p = 0.001), faster response (median time to obtain BM CR were 7 days), and significant better 2-year LFS (50.0% vs 7.1%, p = 0.05). Importantly, there was no significant difference between the two groups with respect to the incidence of pancytopenia (53.8% vs 75%, p>0.05) and treatment related mortality (18.8% vs 7.1%, p>0.05). IFN-α-2b in combination with DLI appears to induce rapid and durable remissions in high risk acute leukemia patients who relapsed following allo-HSCT, with acceptable treatment-related toxicity.